Paper36910902
Irreversible electroporation for prostate cancer using PSMA PET-CT.
Shin D and 14 others. Prostate Int, 2023. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Irreversible electroporation for prostate cancer using PSMA PET-CT. Papers, record 36910902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36910902
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29594551 | Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. | World J Urol | 2018 | https://conductscience.org/library/papers/29594551 | PubMed |
| 2 | 34692586 | Effectiveness of magnetic resonance imaging-targeted biopsy for detection of prostate cancer in comparison with systematic biopsy in our countries with low prevalence of prostate cancer: our first experience after 3 years. | Prostate Int | 2021 | https://conductscience.org/library/papers/34692586 | PubMed |
| 3 | 21679984 | Characterizing clinically significant prostate cancer using template prostate mapping biopsy. | J Urol | 2011 | https://conductscience.org/library/papers/21679984 | PubMed |
| 4 | 27113966 | Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer. | J Urol | 2016 | https://conductscience.org/library/papers/27113966 | PubMed |
| 5 | 21111458 | Renal tissue ablation with irreversible electroporation: preliminary results in a porcine model. | Urology | 2011 | https://conductscience.org/library/papers/21111458 | PubMed |
| 6 | 29188197 | 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. | Prostate Int | 2017 | https://conductscience.org/library/papers/29188197 | PubMed |
| 7 | 17668937 | A study of the immunological response to tumor ablation with irreversible electroporation. | Technol Cancer Res Treat | 2007 | https://conductscience.org/library/papers/17668937 | PubMed |
| 8 | 35510079 | Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer. | Prostate Int | 2022 | https://conductscience.org/library/papers/35510079 | PubMed |
| 9 | 31103721 | Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. | Eur Urol Oncol | 2020 | https://conductscience.org/library/papers/31103721 | PubMed |
| 10 | 35059352 | A systematic review of outcomes after thermal and nonthermal partial prostate ablation. | Prostate Int | 2021 | https://conductscience.org/library/papers/35059352 | PubMed |
| 11 | 21103304 | Irreversible electroporation: a novel image-guided cancer therapy. | Gut Liver | 2010 | https://conductscience.org/library/papers/21103304 | PubMed |
| 12 | 27595377 | New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. | Eur Urol | 2017 | https://conductscience.org/library/papers/27595377 | PubMed |
| 13 | 32458006 | A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer. | Eur J Nucl Med Mol Imaging | 2021 | https://conductscience.org/library/papers/32458006 | PubMed |
| 14 | 34071934 | Irreversible Electroporation for Prostate Cancer. | Life (Basel) | 2021 | https://conductscience.org/library/papers/34071934 | PubMed |
| 15 | 27574821 | Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer. | Eur Urol | 2017 | https://conductscience.org/library/papers/27574821 | PubMed |
| 16 | 35510077 | Initial experience of single-port robot-assisted radical prostatectomy: A single surgeon's experience with technique description. | Prostate Int | 2022 | https://conductscience.org/library/papers/35510077 | PubMed |
| 17 | 31161973 | Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes. | Radiology | 2019 | https://conductscience.org/library/papers/31161973 | PubMed |
| 18 | 21360714 | Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. | J Surg Oncol | 2011 | https://conductscience.org/library/papers/21360714 | PubMed |
| 19 | 22808955 | Radical prostatectomy versus observation for localized prostate cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22808955 | PubMed |
| 20 | 35059353 | Impact of preoperative factors on recovery of continence after artificial urinary sphincter implantation in postprostatectomy incontinence. | Prostate Int | 2021 | https://conductscience.org/library/papers/35059353 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42582915 | Results from the PRESERVE trial: an editorial commentary. | Transl Androl Urol | 2026 | https://conductscience.org/library/papers/42582915 | PubMed |
| 42568760 | The addition of PSMA PET in selecting candidates for prostate cancer focal therapy. | BJUI Compass | 2026 | https://conductscience.org/library/papers/42568760 | PubMed |
| 42382550 | Irreversible electroporation in focal therapy for prostate cancer: current status and future directions. | Prostate Int | 2026 | https://conductscience.org/library/papers/42382550 | PubMed |
| 41908232 | Irreversible electroporation for localized prostate cancer: risk-stratified oncologic outcomes and functional preservation. | Prostate Int | 2026 | https://conductscience.org/library/papers/41908232 | PubMed |
| 41522319 | Focal irreversible electroporation for the treatment of localised prostate cancer: a systematic review. | Transl Androl Urol | 2025 | https://conductscience.org/library/papers/41522319 | PubMed |
| 41472932 | 18F-florastamin positron emission tomography/computed tomography in men with clinical suspicion of prostate cancer: A phase I prospective study. | Prostate Int | 2025 | https://conductscience.org/library/papers/41472932 | PubMed |
| 40940959 | Oncological Efficacy and Safety of Minimally Invasive Focal and Whole-Gland Interventions in the Treatment of Low- and Intermediate-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40940959 | PubMed |
| 40647385 | Oncological and Functional Outcomes of Hemi-Ablation Versus Focal Ablation for Localized Prostate Cancer Using Irreversible Electroporation. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40647385 | PubMed |
| 40213348 | Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer. | Prostate Int | 2025 | https://conductscience.org/library/papers/40213348 | PubMed |
| 39939364 | Is there a role of PSMA-PET in focal therapy planning and follow-up? | Prostate Cancer Prostatic Dis | 2026 | https://conductscience.org/library/papers/39939364 | PubMed |
| 39028129 | Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review. | World J Mens Health | 2025 | https://conductscience.org/library/papers/39028129 | PubMed |
| 37627908 | Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer. | Diagnostics (Basel) | 2023 | https://conductscience.org/library/papers/37627908 | PubMed |
| 37444450 | Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37444450 | PubMed |
| 37409098 | Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis. | Prostate Int | 2023 | https://conductscience.org/library/papers/37409098 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FOLH1 | 2346 | PubTator's text mining | https://conductscience.org/library/genes/2346 | NCBI Gene |
| KLK3 | 354 | PubTator's text mining | https://conductscience.org/library/genes/354 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36910902
GET https://conductscience.org/api/papers/v1/36910902/references?page=2